TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03290131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Arbaclofen Extended Release Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Arbaclofen Extended Release Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03327935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: 150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: 150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
Study: NCT05290636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching intervention program
Description: Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
Study: NCT01970423

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT
Description: The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.

Intervention type: DEVICE
Group type: OTHER
Intervention: conventional right ventricular stimulation
Study: NCT04045041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: An acceptance based intervention with focus on exposure.
Study: NCT04331431

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spinal cord tumor resection
Description: Excision of intradural tumors
Study: NCT01040806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive their usual medical care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Peer health coaches will counsel patients with diabetes
Study: NCT03417648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
Study: NCT00646217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Care Talk
Description: 6 weekly telephone sessions
Study: NCT01035021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of rocuronium when the LMA is inserted
Description: Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of rocuronium when the LMA is inserted
Description: Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
Study: NCT04592666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: the standard therapy of single agent almonertinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: the standard therapy of single agent almonertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5
Study: NCT02116374

Intervention type: OTHER
Intervention: Physiopathology study
Study: NCT03225950

Intervention type: OTHER
Intervention: In vitro stimulation of blood with periodontitis-associated- and control bacteria
Description: Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.

Intervention type: OTHER
Intervention: In vitro stimulation of blood with periodontitis-associated- and control bacteria
Description: Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.

Intervention type: OTHER
Intervention: In vitro stimulation of blood with periodontitis-associated- and control bacteria
Description: Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-CCP- and anti-P.g.-antibodies titers
Description: Anitbody titers will be measured in saliva and serum samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-CCP- and anti-P.g.-antibodies titers
Description: Anitbody titers will be measured in saliva and serum samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-CCP- and anti-P.g.-antibodies titers
Description: Anitbody titers will be measured in saliva and serum samples.

Intervention type: GENETIC
Intervention: Analysis of selected single nucleotide polymorphisms (SNPs)
Description: DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.

Intervention type: GENETIC
Intervention: Analysis of selected single nucleotide polymorphisms (SNPs)
Description: DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.

Intervention type: GENETIC
Intervention: Analysis of selected single nucleotide polymorphisms (SNPs)
Description: DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontitis-associated bacteria presence
Description: Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontitis-associated bacteria presence
Description: Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontitis-associated bacteria presence
Description: Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
Study: NCT02763410

Intervention type: OTHER
Intervention: PRBC transfusion

Intervention type: OTHER
Intervention: PRBC transfusion
Study: NCT04510870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl infusion
Description: Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl infusion
Description: Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
Study: NCT00734318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 250/10 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 50/5 micrograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide pMDI 250 micrograms
Study: NCT00519909

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat
Study: NCT04344886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional (dual-phase) SPECT/CT
Description: Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-phase SPECT/CT
Description: Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional minimally-invasive radio-guided parathyroidectomy
Description: Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualised minimally-invasive radio-guided parathyroidectomy
Description: Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
Study: NCT02861716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study: NCT00519909

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat

Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat
Study: NCT00838175

Intervention type: PROCEDURE
Intervention: suture mediated closure
Description: Suture mediated closure of femoral venous access
Study: NCT01994369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study: NCT03621566

Intervention type: OTHER
Intervention: No intervention
Description: Routine care (registry)
Study: NCT06385483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study: NCT02284477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non- PVC containing packing materials
Description: Beverage which was stored in glass bottle for 24 hours in 4 ℃.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVC containing packing materials
Description: Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
Study: NCT04725435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking Position
Description: Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure.
Study: NCT03569670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior stabilized all-polyethylene tibial component
Description: Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate retaining all-polyethylene tibial component
Description: Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
Study: NCT00866632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
Study: NCT01248299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FU-CDDP
Description: every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP
Description: every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF
Description: every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
Study: NCT01591473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 50 ug
Description: Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 50 ug
Description: Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 200 ug
Description: Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 500 ug
Description: Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 1250 ug
Description: Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days
Study: NCT03493191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5μg/kg SHR0410
Description: a single dose of 0.5μg/kg SHR0410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1μg/kg SHR0410
Description: a single dose of 2μg/kg SHR0410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2μg/kg SHR0410
Description: a single dose of 2μg/kg SHR0410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5μg/kg SHR0410
Description: a single dose of 5μg/kg SHR0410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10μg/kg SHR0410
Description: a single dose of 10μg/kg SHR0410
Study: NCT01591473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days
Study: NCT03493191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20μg/kg SHR0410
Description: a single dose of 20μg/kg SHR0410
Study: NCT00318890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
Study: NCT03254134

Intervention type: DRUG
Intervention: Warfarin
Description: patients treated with warfarin

Intervention type: DRUG
Intervention: Dabigatran
Description: patients treated with Dabigatran
Study: NCT04974970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Immunotherapy
Description: Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
Study: NCT01434290

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 36.25 Gy IMRT
Description: 36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 51.6 Gy IMRT
Description: 51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
Study: NCT03900299

Intervention type: PROCEDURE
Group type: OTHER
Intervention: oncoplastic breast surgery
Description: oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
Study: NCT01823874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality distraction
Description: Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality distraction
Description: Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
Study: NCT03688321

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsule GR-1 and RC-14
Description: Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
Study: NCT01858012

Intervention type: BEHAVIORAL
Intervention: Moderate alcohol cessation
Description: patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement

Intervention type: BEHAVIORAL
Intervention: Moderate alcohol cessation
Description: patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
Study: NCT03658083

Intervention type: PROCEDURE
Intervention: Thoracotomy
Description: Open surgery

Intervention type: PROCEDURE
Intervention: Robotic-assisted thoracic surgery
Description: Minimally invasive surgery